• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation.

作者信息

Ding Kaibo, Peng Zhongsheng, Xu Yanjun

机构信息

Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.

Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China.

出版信息

Genes Dis. 2024 Sep 7;12(2):101408. doi: 10.1016/j.gendis.2024.101408. eCollection 2025 Mar.

DOI:10.1016/j.gendis.2024.101408
PMID:39830031
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11742358/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/11742358/ce6bf7d93194/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/11742358/ce6bf7d93194/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cd8/11742358/ce6bf7d93194/gr1.jpg

相似文献

1
Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation.三联疗法可克服反式和顺式/ L718Q突变中的第三代EGFR TKI耐药EGFR-L858R/T790M/C797S。
Genes Dis. 2024 Sep 7;12(2):101408. doi: 10.1016/j.gendis.2024.101408. eCollection 2025 Mar.
2
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, -G796s/-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report.奥希替尼、布加替尼和贝伐单抗联合治疗携带L858R、T790M、-G796s/-C797s三重表皮生长因子受体（EGFR）突变的肺腺癌：一例报告
Respir Med Case Rep. 2022 Jan 10;36:101582. doi: 10.1016/j.rmcr.2022.101582. eCollection 2022.
3
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.CH7233163 克服奥希替尼耐药的 EGFR-Del19/T790M/C797S 突变。
Mol Cancer Ther. 2020 Nov;19(11):2288-2297. doi: 10.1158/1535-7163.MCT-20-0229. Epub 2020 Sep 17.
4
Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.病例报告：奥希替尼进展后，一名携带EGFR L858R-T790M-cis-G796S和L718Q耐药突变的非小细胞肺癌患者对布加替尼、西妥昔单抗联合埃克替尼的联合治疗产生持久反应。
Front Oncol. 2022 Apr 21;12:875313. doi: 10.3389/fonc.2022.875313. eCollection 2022.
5
Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations.在伴有获得性EGFR L858R/T790M/C797S突变的晚期非小细胞肺癌中，基于配对NGS指导的EGFR/NTRK/MET联合抑制反应
J Natl Compr Canc Netw. 2024 Dec 27;23(2):e247070. doi: 10.6004/jnccn.2024.7070.
6
Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q.针对罕见的奥希替尼耐药突变EGFR L718Q的潜在治疗策略。
J Thorac Dis. 2020 May;12(5):2771-2780. doi: 10.21037/jtd.2020.03.29.
7
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.应用数字液滴 PCR 对日本非小细胞肺癌患者进行连续的游离细胞 DNA 评估，监测表皮生长因子受体 C797S 突变。
Cancer Sci. 2021 Jun;112(6):2371-2380. doi: 10.1111/cas.14879. Epub 2021 May 2.
8
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.布加替尼与西妥昔单抗联合治疗携带有 EGFR 激活突变、T790M 和 cis-C797S 三重突变的肺腺癌的疗效。
J Thorac Oncol. 2020 Aug;15(8):1369-1375. doi: 10.1016/j.jtho.2020.04.014. Epub 2020 Apr 27.
9
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment.表皮生长因子受体（EGFR）第18外显子中的L718Q/V突变介导对奥希替尼的耐药性：临床特征与治疗
Discov Oncol. 2022 Aug 9;13(1):72. doi: 10.1007/s12672-022-00537-7.
10
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report.奥希替尼、贝伐单抗和布加替尼联合治疗携带L858R、T790M和-C797S三重EGFR突变的肺腺癌：一例报告
Onco Targets Ther. 2018 Sep 6;11:5545-5550. doi: 10.2147/OTT.S170358. eCollection 2018.

引用本文的文献

1
EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review).非小细胞肺癌中的表皮生长因子受体（EGFR）突变：分类、特征及对第三代EGFR酪氨酸激酶抑制剂的耐药性（综述）
Oncol Lett. 2025 Jun 2;30(2):375. doi: 10.3892/ol.2025.15121. eCollection 2025 Aug.

本文引用的文献

1
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.EGFR C797X 突变型肺癌的等位基因背景定义了具有异质性基因组景观和不同临床结局的四个亚型。
J Thorac Oncol. 2024 Apr;19(4):601-612. doi: 10.1016/j.jtho.2023.11.016. Epub 2023 Nov 20.
2
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment.表皮生长因子受体（EGFR）第18外显子中的L718Q/V突变介导对奥希替尼的耐药性：临床特征与治疗
Discov Oncol. 2022 Aug 9;13(1):72. doi: 10.1007/s12672-022-00537-7.
3
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance Mutations.
一线奥希替尼耐药突变的药物敏感性和等位基因特异性。
Cancer Res. 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819. Epub 2020 Mar 19.
4
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.阿弗替尼（AST2818）在晚期EGFR T790M突变非小细胞肺癌患者中的安全性、临床活性和药代动力学
J Thorac Oncol. 2020 Jun;15(6):1015-1026. doi: 10.1016/j.jtho.2020.01.010. Epub 2020 Jan 30.
5
Tumour heterogeneity and resistance to cancer therapies.肿瘤异质性与癌症治疗耐药性。
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. doi: 10.1038/nrclinonc.2017.166. Epub 2017 Nov 8.